SprayClinical Overview
Fluticasone Propionate / Fluticasone Furoate Nasal Spray (27.5mcg, 50mcg per spray) is a synthetic trifluorinated corticosteroid on the WHO Model List of Essential Medicines. It binds with exceptionally high affinity to glucocorticoid receptors in the nasal mucosa, inhibiting mediator release (histamine, leukotrienes, cytokines) with virtually negligible systemic oral bioavailability (<0.1%). Indicated for management of seasonal allergic rhinitis, perennial allergic rhinitis, and nasal polyposis.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Adults: 2 sprays in each nostril once daily, preferably in the morning (or 1 spray twice daily); reduce to 1 spray per nostril daily once symptoms are controlled. Point spray toward the lateral nasal wall, NOT directly at the nasal septum. Full clinical benefit may take several days of regular use.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Epistaxis (mild nasal bleeding), nasal dryness, crusting, headache, pharyngitis. Rare/Severe: Nasal septal perforation, localized Candida albicans infection, and glaucoma / cataracts with long-term excessive use.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Direct spray tip away from the nasal septum to prevent mucosal erosion and septal perforation. Use regularly for optimal prophylactic efficacy; not an immediate-acting decongestant. Periodically inspect nasal mucosa during long-term use.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, pulmonological diagnosis, or respiratory management recommendations. Inhalation therapies and allergy medications should be used strictly under the guidance of a qualified pulmonologist or registered medical practitioner.
Salmeterol 50mcg + Fluticasone 250mcg Rotacaps
Salmeterol Xinafoate (25mcg/50mcg) and Fluticasone Propionate (100mcg/250mcg/500mcg Inhaler, Rotacaps) is a benchmark inhaled corticosteroid and long-acting beta-2 agonist combination on the WHO Model List of Essential Medicines. Fluticasone exerts profound local anti-inflammatory, immunosuppressive, and anti-edematous effects in bronchial mucosa with low systemic bioavailability due to extensive first-pass metabolism. Salmeterol provides long-acting bronchodilation lasting over 12 hours via persistent beta-2 receptor activation. Indicated for maintenance therapy of persistent bronchial asthma and maintenance treatment of airflow obstruction in patients with severe COPD and recurrent exacerbations.
Fluticasone Propionate Respules 0.5mg per 2ml
Fluticasone Propionate Respules (0.5mg per 2ml) is an inhaled corticosteroid nebulizer suspension on the WHO Model List framework. Delivers high topical anti-inflammatory potency to bronchial mucosal tissues. Indicated for maintenance management of severe persistent asthma and acute exacerbations in pediatric and adult patients unable to coordinate inhaler devices.
Azelastine Hydrochloride 140mcg + Fluticasone Propionate 50mcg Nasal Spray
Azelastine Hydrochloride (140mcg) and Fluticasone Propionate (50mcg) Nasal Spray is a fixed-dose second-generation H1-antihistamine and corticosteroid combination on the WHO Model List framework. Azelastine provides rapid-onset (within 15 minutes) blockade of histamine H1 receptors, relieving sneezing, nasal itching, and rhinorrhea. Fluticasone provides sustained 24-hour suppression of mucosal inflammation, relieving stubborn nasal congestion. Proven significantly superior to either monotherapy for Moderate-to-Severe Allergic Rhinitis and seasonal rhinoconjunctivitis.
Salmeterol 25mcg + Fluticasone Propionate 250mcg Inhaler
Salmeterol Xinafoate (25mcg/50mcg) and Fluticasone Propionate (100mcg/250mcg/500mcg Inhaler, Rotacaps) is a benchmark inhaled corticosteroid and long-acting beta-2 agonist combination on the WHO Model List of Essential Medicines. Fluticasone exerts profound local anti-inflammatory, immunosuppressive, and anti-edematous effects in bronchial mucosa with low systemic bioavailability due to extensive first-pass metabolism. Salmeterol provides long-acting bronchodilation lasting over 12 hours via persistent beta-2 receptor activation. Indicated for maintenance therapy of persistent bronchial asthma and maintenance treatment of airflow obstruction in patients with severe COPD and recurrent exacerbations.